Custom Monoclonal Antibody Production for Phosphorylation Research

Custom Monoclonal Antibody Production for Phosphorylation Research

Home / Services / Custom Antibody for Phosphorylation Research / Custom Monoclonal Antibody Production for Phosphorylation Research

Custom Monoclonal Antibody Production for Phosphorylation Research

INQUIRY

Creative BioMart is confident to provide our customers with high-quality and highly specific monoclonal antibodies for their kinase/phosphatase biology research and pharmaceutical development projects. We offer a fully custom service package from antigen preparation to antibody characterization to ensure that our customers receive the required antibodies for their downstream applications as soon as possible.

Background

Monoclonal antibodies (mAbs) are antibodies produced by a single clone of B lymphocytes and therefore have monovalent affinity, binding only to the same epitope. With the rapid development of technology, it is possible to produce different types of mAbs that can recognize and specifically bind to almost any suitable substance, thus for different downstream applications such as detection and purification. mAbs have become an important tool in life science research and medicine. The requirements for antibody production and purification are different depending on specific research needs.

Monoclonal antibodies have tremendous applications not only in basic research but also in the field of diagnostics, therapeutics and targeted drug delivery systems. Under pathological conditions, protein phosphorylation is often deregulated. Emerging evidence suggests that kinase/phosphatase kinetics are critical for network function and cell-fate decisions, making these enzymes potential drug targets for the treatment of many diseases. Monoclonal antibodies targeting kinases and phosphatases have continued to be one of the fastest growing classes of therapeutic molecules.

Comparison of monoclonal antibodies (mAbs) and tyrosine kinase inhibitor (TKI) activity in receptor tyrosine kinase (RTK).

Figure 1. Comparison of monoclonal antibodies (mAbs) and tyrosine kinase inhibitor (TKI) activity in receptor tyrosine kinase (RTK). (Kim K & Khang D., 2020)

Capabilities

Creative BioMart has extensive experience in custom monoclonal antibody production. We have advanced technology platforms and professional scientific team to maximize the chance of producing specific and high-affinity mAbs within a short period of time. We also have the capacity to manufacture antibodies in large quantities.

Platforms for Custom Monoclonal Antibody Production – Creative BioMart

Service Options

Creative BioMart offers a wide range of flexible and customizable service options to handle projects of all levels of complexity. Whether the production process is challenging or has specific screening requirements, we will do our best to optimize the custom project to perfectly meet your research requirements.

Antigens
Peptides Natural proteins Recombinant proteins DNA
Cells Virus Small molecules Hapten
Species
Alligator Bovine Camel Cat
Chicken Dog Donkey Duck
Ferret Goat Goose Guinea Pig
Hamster Horse Human Monkey
Mouse Ostrich Porcine Quail
Rabbit Rat Shark Sheep
Turkey Zebrafish More user-defined options
Additional Services
Hybridoma sequencing Antibody affinity maturation Cell banking Scale up production
Blocking peptide Heterogeneous recombination Antibody engineering Therapeutic antibodies

If you can't find what you are looking for in the options above, please fill out the online inquiry form and let us know more details.

Standard Service Process

Standard Service Process

Highlights

Highlights

Creative BioMart provides comprehensive and flexible custom monoclonal antibody production services to meet the individual needs of our customers. Our advanced technology platform coupled with a large product portfolio has enabled us to successfully complete numerous challenging projects, helping our customers save time and effort. A large collection of ready-to-use monoclonal antibodies is also available.

If you are interested in our services or products, please do not hesitate to contact us.

Reference

  • Kim K & Khang D. Past, Present, and Future of Anticancer Nanomedicine. International Journal of Nanomedicine, 2020, 15: 5719.
For research use only. Not intended for any clinical use.